Cartesian Therapeutics Statistics
Total Valuation
RNAC has a market cap or net worth of $185.46 million. The enterprise value is $122.82 million.
| Market Cap | 185.46M |
| Enterprise Value | 122.82M |
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RNAC has 30.50 million shares outstanding. The number of shares has increased by 9.08% in one year.
| Current Share Class | 30.50M |
| Shares Outstanding | 30.50M |
| Shares Change (YoY) | +9.08% |
| Shares Change (QoQ) | +1.50% |
| Owned by Insiders (%) | 52.87% |
| Owned by Institutions (%) | 21.58% |
| Float | 11.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 180.93 |
| Forward PS | 1,236.39 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 119.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.38
| Current Ratio | 8.38 |
| Quick Ratio | 7.84 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -36.09 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -19.23% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -36.82% |
| Weighted Average Cost of Capital (WACC) | 7.26% |
| Revenue Per Employee | $13,667 |
| Profits Per Employee | -$1.70M |
| Employee Count | 75 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -9.19M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.50% in the last 52 weeks. The beta is 0.76, so RNAC's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -18.50% |
| 50-Day Moving Average | 7.08 |
| 200-Day Moving Average | 7.61 |
| Relative Strength Index (RSI) | 38.57 |
| Average Volume (20 Days) | 129,536 |
Short Selling Information
The latest short interest is 1.92 million, so 6.28% of the outstanding shares have been sold short.
| Short Interest | 1.92M |
| Short Previous Month | 1.88M |
| Short % of Shares Out | 6.28% |
| Short % of Float | 16.34% |
| Short Ratio (days to cover) | 13.62 |
Income Statement
In the last 12 months, RNAC had revenue of $1.03 million and -$127.46 million in losses. Loss per share was -$4.53.
| Revenue | 1.03M |
| Gross Profit | -69.18M |
| Operating Income | -102.59M |
| Pretax Income | -136.65M |
| Net Income | -127.46M |
| EBITDA | -99.81M |
| EBIT | -102.59M |
| Loss Per Share | -$4.53 |
Balance Sheet
The company has $122.98 million in cash and $60.34 million in debt, with a net cash position of $62.64 million or $2.05 per share.
| Cash & Cash Equivalents | 122.98M |
| Total Debt | 60.34M |
| Net Cash | 62.64M |
| Net Cash Per Share | $2.05 |
| Equity (Book Value) | -130.47M |
| Book Value Per Share | -4.28 |
| Working Capital | 115.80M |
Cash Flow
In the last 12 months, operating cash flow was -$88.66 million and capital expenditures -$1.23 million, giving a free cash flow of -$89.89 million.
| Operating Cash Flow | -88.66M |
| Capital Expenditures | -1.23M |
| Depreciation & Amortization | 2.79M |
| Net Borrowing | 46.03M |
| Free Cash Flow | -89.89M |
| FCF Per Share | -$2.95 |
Margins
| Gross Margin | n/a |
| Operating Margin | -10,009.17% |
| Pretax Margin | -13,332.10% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RNAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.08% |
| Shareholder Yield | -9.08% |
| Earnings Yield | -74.46% |
| FCF Yield | -48.47% |
Analyst Forecast
The average price target for RNAC is $33.67, which is 453.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $33.67 |
| Price Target Difference | 453.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 99.02% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on April 5, 2024. It was a reverse split with a ratio of 1:30.
| Last Split Date | Apr 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
RNAC has an Altman Z-Score of -4.45 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.45 |
| Piotroski F-Score | 2 |